Welcome to our dedicated page for Ingevity SEC filings (Ticker: NGVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ingevity Corporation filings document formal disclosure for its specialty materials business, public-company governance, and capital structure. Form 8-K reports cover operating results, segment reporting presentation, credit agreement amendments, material agreements, and completed dispositions of North Charleston crude tall oil refinery assets and the majority of the Industrial Specialties product line.
Proxy and annual-meeting filings disclose director elections, board structure, executive compensation matters, shareholder voting results, and amendments to the company’s equity incentive plan. The filing record also includes disclosures tied to financing arrangements, continuing-operations measures, and governance matters affecting Ingevity’s common stock as a NYSE-listed issuer.
Ingevity Corp director Kevin J. Willis reported an award of 397 shares of common stock-equivalent deferred stock units, valued using a reference price of $72.58 per share. Following this grant, his directly owned and deferred stock unit-equivalent holdings total 11,478 shares.
These units represent vested deferred stock units received in lieu of quarterly director fees. Under Ingevity’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan, the units will convert into an equal number of common shares when his board service ends.
Ingevity Corp director Francis David Segal reported an acquisition of 328 shares of Common Stock, recorded as a grant or award valued at $72.58 per share. Following this award, his direct holdings increased to 8,612 shares.
According to the footnote, the 328 vested deferred stock units were granted under Segal’s election to receive DSUs instead of quarterly director fees. These DSUs will convert into an equal number of Ingevity common shares when his board service ends, under the company’s deferred compensation and 2025 omnibus incentive plans.
Cotterman Ryan Joseph reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp reported that VP and Chief Accounting Officer Ryan Joseph Cotterman received an equity grant of 2,063 shares of common stock as a compensation award. The grant represents restricted stock units under the Ingevity Corporation 2025 Omnibus Incentive Plan, issued at no cash cost to him.
These restricted stock units will vest in three equal installments on June 22, 2027, 2028, and 2029, tying part of his compensation to future service and company performance. Following this award, Cotterman directly holds 2,063 shares linked to this grant.
Ingevity Corp executive Ryan Joseph Cotterman, who serves as VP and Chief Accounting Officer, has filed a Form 3 insider ownership report. The filing lists him as an officer of the company and does not report any share purchase, sale, or other insider transactions in this excerpt.
Ingevity Corporation appointed Ryan Cotterman, age 44, as Vice President, Chief Accounting Officer and principal accounting officer effective June 22, 2026. He brings prior senior accounting leadership experience from Ralliant Corporation, Cornerstone Building Brands, Advance Auto Parts, and 14 years at Ernst & Young.
His initial annual base salary will be $345,000 with an annual bonus target of 40% of base salary and a long-term incentive opportunity equal to 65% of base salary beginning in 2027. Cotterman will receive a one-time sign-on cash bonus of $40,000 and restricted stock units with a grant date target value of $150,000, vesting over three years.
The company states there are no selection arrangements, family relationships, or related-party transactions requiring disclosure in connection with this appointment.
Ingevity Corp senior vice president and Chief HR Officer Terrance M. Dyer reported open-market sales of company common stock. On May 28, 2026, he sold a total of 496 shares of Ingevity common stock in three transactions at prices between $68.45 and $68.57 per share.
Wellington Management Group LLP and affiliated entities filed an amended Schedule 13G/A reporting beneficial ownership of 1,494,292 shares of Ingevity Corporation common stock, representing 4.24% of the class as reported. The cover lists shared voting power of 1,251,096 and shared dispositive power of 1,494,292 as of 03/31/2026. The filing states these shares are held of record by clients of Wellington investment advisers and identifies the relevant holding and adviser entities. The amendment is signed by Matthew Revell on 05/15/2026.
Ingevity Corporation reported higher first‑quarter 2026 earnings, driven by a major divestiture gain despite significant litigation charges. Net sales from continuing operations rose to $258.0 million from $247.9 million, as better pricing and mix in Performance Materials and pavement technologies offset flat volumes.
Net income from continuing operations declined to $23.4 million from $29.1 million, mainly because of a $16.2 million litigation charge tied to the BASF antitrust verdict and related costs. Including discontinued operations, total net income increased to $59.8 million, helped by a $55.6 million gain on the sale of the industrial specialties product line and crude tall oil refinery, which generated $93.1 million of cash proceeds.
Performance Materials segment EBITDA grew to $92.0 million on stronger pricing, mix and utilization, while Performance Chemicals segment EBITDA fell to $0.6 million amid weaker road markings performance. Ingevity ended the quarter with $95.4 million in cash and $1.21 billion of debt and amended its revolving credit facility, reducing commitments to $750 million and extending maturity to 2031.
Ingevity Corporation reported mixed but generally stable first quarter 2026 results. Net sales from continuing operations were $258.0 million, up 4% from a year earlier, driven mainly by pricing actions and favorable foreign exchange. Net income from continuing operations was $23.4 million, or $0.65 per diluted share, down from $29.1 million and $0.79, reflecting $22.7 million of pre-tax special charges, including a $16.2 million litigation-related reimbursement to BASF.
On a non-GAAP basis, adjusted earnings from continuing operations rose to $41.4 million, with diluted adjusted EPS of $1.15 versus $1.01, and adjusted EBITDA was $91.5 million, essentially flat with the prior year and a 35.5% margin. Performance Materials led growth, with 6% higher sales and segment EBITDA up 10%.
The company completed the sale of its North Charleston refinery assets and most Industrial Specialties products for about $93 million and divested the Road Markings product line for about $65 million. Free cash flow was negative $12.3 million, partly due to seasonal working capital, while share repurchases reached $52 million and net debt ratio was 2.6x. Ingevity reaffirmed full-year 2026 guidance, targeting net sales of $1.05–$1.15 billion, adjusted EBITDA of $370–$395 million, adjusted EPS of $4.70–$5.20, and free cash flow of $215–$245 million, excluding a $113.2 million litigation settlement payment to BASF.
PLATT PHILLIP JOHN reported acquisition or exercise transactions in this Form 4 filing.
Ingevity Corp senior vice president of finance and chief accounting officer Phillip John Platt received a grant of 1,262 restricted stock units (RSUs) of common stock on May 1, 2026. This was awarded under the Ingevity Corporation 2025 Omnibus Incentive Plan and is compensation rather than a market purchase.
The RSUs will vest in three equal installments on May 1, 2027, 2028, and 2029, meaning the shares are earned over time if service conditions are met. After this award, Platt directly holds 31,633 shares of Ingevity common stock, which includes 422 shares purchased through the company’s Employee Stock Purchase Plan for the period from January 1, 2026 to March 31, 2026 at a price equal to 85% of the December 31, 2025 closing price.